Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 329.99 Mil Enterprise Value: 197.14 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Oncopeptides AB (publ) To Present Updated Ocean Results Call Transcript

Jul 08, 2021 / 09:00AM GMT
Release Date Price: kr52.1 (-25.10%)
Operator

Welcome to the Oncopeptides Audiocast Press Conference 2021. (Operator Instructions) Today, I'm pleased to present CEO, Marty J. Duvall. Please go ahead. Your line is open.

Martin J. Duvall;publ;CEO
Oncopeptides AB

()-

Great, thank you. And good morning, everyone. And pleased to provide, today, updated results on the OCEAN trial and also a communication of a partial clinical development hold for our lead product, melflufen. So joining me on the call, Slide 2, will be Dr. Klaas Bakker, our Chief Medical Officer; and also Jakob Lindberg, our Chief Scientific Officer. And on Slide 3, we will be making forward-looking statements. So I ask everyone to look at our submissions and representations for complete fairness and accuracy that you'll find on our website and in other filings.

So looking at Slide 4. So what are the key takeaways here? And this is mostly associated, of course, with the OCEAN trial. And recall that this is a bold head-to-head study versus pomalidomide, so 2 very different mechanisms of action in patients

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot